This protocol describes the common methodology to be applied to established health data registries across seven participating EU/EEA Member States to estimate vaccine effectiveness for Coronavirus disease 2019 (COVID-19) in children and adolescents aged 5-17 years old.
This protocol presents a common updated methodology to estimate vaccine effectiveness (VE) for COVID-19, using established health data registries in participating European Union and European Economic Area (EU/EEA) countries.
This core protocol for ECDC studies of VE against hospitalisation with SARI laboratory-confirmed with SARS-CoV-2 or with influenza, version 3.0, represents an update to the main elements for a multi-country hospital-based study of COVID-19 vaccine effectiveness in patients hospitalised with SARI, initially published as version 1.0 [5], updated to version 2.0 [6].
This generic protocol for ECDC studies describes the design and methods for a prospective multi-country cohort study of hospital-based healthcare workers (HCWs) to evaluate the effectiveness of COVID-19 vaccine in preventing laboratory-confirmed SARS-CoV-2 infection.
Influenza is a disease of public health importance due to the substantial seasonal morbidity and mortality and the high pandemic potential of its aetiologic agents, influenza viruses.
Joint statement by the European Centre for Disease Prevention and Control, European Chemicals Agency, European Environment Agency, European Food Safety Authority and European Medicines Agency.
This document presents the core protocol for ECDC studies of CVE and IVE against symptomatic laboratory-confirmed influenza or SARS-CoV-2 infection, respectively, at primary care level.
Prevalence data from sources such as population surveys can be a useful complement to case based surveillance data for hepatitis B. Case-based surveillance has limitations as most diagnosed cases are chronic in nature and detection of cases depends largely on testing practices. Prevalence data can therefore contribute towards a fuller understanding of the epidemiology of hepatitis B.
The Epidemic Intelligence Information System (EPIS) is a web-based communication platform that allows nominated public health experts to exchange technical information to assess whether current and emerging public health threats have a potential impact in the European Union (EU).
This document offers an overview of the available scientific evidence and epidemiological situation and provides public health considerations to support discussions and decisions on the planning and implementation of COVID-19 vaccination campaigns for 2023.